<DOC>
	<DOC>NCT00730652</DOC>
	<brief_summary>To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.</brief_summary>
	<brief_title>Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma</brief_title>
	<detailed_description>Dose-escalation, multidose study of MDX-1411, a fully human nonfucosylated monoclonal antibody (mAb) targeting the CD70 transmembrane cell-surface protein, which is highly expressed in B-cell malignancies such as CLL and MCL.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<criteria>Histologically confirmed diagnosis of relapsed/refractory MCL or hematologically/bone marrow confirmed relapsed/refractory CLL that is not amenable to cure by surgery or other means and has failed at least 1 prior systemic therapy; Subjects may have been treated with up to 6 prior systemic therapies for relapsed/refractory disease or have become intolerant to a systemic therapy For MCL, must have measurable disease At least 4 weeks since the last systemic therapy, including RT, for the treatment of MCL/CLL; At least 4 weeks since taking any corticosteroids prior to the first dose of MDX1411 ECOG Performance Status 0 to 2; No known positivity for human immunodeficiency virus (HIV) and no active infection with Hepatitis B or Hepatitis C; History of severe hypersensitivity reactions to other monoclonal antibodies; Use of other investigational drugs within 30 days before study drug administration Prior treatment with any other antiCD70 antibody; Active infection requiring i.v. systemic therapy within 4 weeks of receiving the first dose of MDX1411; Evidence of bleeding diathesis or coagulopathy; Active autoimmune disease requiring immunosuppressive therapy; Known current drug or alcohol abuse; Underlying medical conditions that will make the administration of MDX1411 hazardous</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Medarex Inc.</keyword>
</DOC>